(NEOP) - Lymphoseek....
I got in this the other day at $2.67.
I'm sure you are aware since you traded it before, but Lymphoseek has a lot of advantages over the current blue dye/colloid method. I'm not too familiar with this stuff but it is my understanding that the current method is used as an "off-label" use and is not reimbursable from insurance, etc. Lymphoseek would have an advantage because it would be reimbursable by medicare and private insurers. Also, from the trial results it would appear Lymphoseek may have a "superiority" claim over the current methods also. This is important because all analyst targets and revenue estimates were mostly based on Lymphoseek selling for around $150-$200 a dose whereas the current method is more around $400-500.
In this case, either Lymphoseek could easily/quickly gain market share - or since they would be reimbursable and maybe superior - perhaps they could raise their selling point close to that of the blue dye - garnering far more revenue than some of the analyst had estimated.
Other advantages of lymphoseek are described by this excerpt.
"In pre-clinical and FDA clinical trials to date, Lymphoseek has demonstrated superior site clearance, clearing the injection site between four and eight times faster than the older Sulpher colloid products. Lymphoseek begins clearing as quickly as 15 minutes after injection, saving time in the operating room. In a direct comparison in clinical trials, five hours after injection 95% of the Sulpher Colloid based product still remained at the injection site, whereas 75% of Lymphoseek had cleared the site and migrated into the lymphatics."
Looking forward to the results to come out. This company should be valued higher based on Lymphoseek alone - not to mention the rest of the pipeline (Rigscan). I'm hopeful that they can uplist soon.
News 
Market Data 
Discover 
AI
